AN-1792 (Elan).

Abstract

Elan is developing AN-1792 as a potential immunotherapy for Alzheimer's disease (AD). It is currently in phase I trials [350904]. Phase II/III trials, running in parallel in the US and UK, are expected to start by the end of 2001 [375061], [383226], [401966]. American Home Products (AHP) are collaborating with Elan on research and development of an immunotherapy directed towards the beta-amyloid peptide, including AN-1792 and other potential products [361702]. In September 2000, an agreement was established between Elan, AHP and Cambridge Antibody Technology (CAT), whereby CAT are investigating anti-beta-amyloid human antibodies [394844]. In July 2000, Merrill Lynch predicted a possible late-2001 entry into pivotal trials with a potential NDA filing in 2004 [375966]. The clinical program is expected to take approximately four years [339630]. In April 2001, ABN Amro Hoare Govett stated that, if data from the large phase II trial expected to start late in 2001 satisfied FDA requirements, then Elan might be able to file an NDA in 2003, with a potential launch in 2005 [407412].

• Authors: U Thatte
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 5 Pg. 663-7 (May 2001) ISSN: 1472-4472 [Print] England
• PMID: 11569944 (Publication Type: Journal Article, Review)

Chemical References

• AN-1792
• Adjuvants, Immunologic
• Amyloid
• Amyloid beta-Peptides
• Vaccines

Topics

• Adjuvants, Immunologic (pharmacology, therapeutic use, toxicity)
• Alzheimer Disease (drug therapy)
• Amyloid (immunology)
• Amyloid beta-Peptides (pharmacology, therapeutic use, toxicity)
• Animals
• Clinical Trials as Topic
• Humans
• Structure-Activity Relationship
• Vaccines (pharmacology, therapeutic use, toxicity)